MGMT and glioblastoma: The trial, called ARISTOCRAT, is a phase II, multi-center, double-blind, placebo-controlled, randomized trial, aiming to compare the Nabiximols with placebo in patients with recurrent MGMT-methylated GBM, treated with TMZ.